Therapeutic Asset Ratings
149 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Eloxatin
Pancreatic Ductal Adenocarcinoma
Jonsson Comprehensive Cancer Center
P4
BB
(64)
FLUOROURACILUM
Pancreatic Ductal Adenocarcinoma
Jonsson Comprehensive Cancer Center
P3
B
(63)
Capecitabine
Pancreatic Ductal Adenocarcinoma
Shenyang Sunshine Pharmaceutical Co., LTD.
P3
B
(62)
Calcium folinate pentahydrate
Pancreatic Ductal Adenocarcinoma
Jonsson Comprehensive Cancer Center
P3
B
(61)
Cyclophosphamide
Pancreatic Ductal Adenocarcinoma
Beijing Biotech
P2
B
(61)
Durvalumab
Pancreatic Ductal Adenocarcinoma
Jonsson Comprehensive Cancer Center
P2
B
(61)
S-1
Pancreatic Ductal Adenocarcinoma
Genentech, Inc.
P2/3
B
(61)
Irinotecan
Pancreatic Ductal Adenocarcinoma
Jonsson Comprehensive Cancer Center
P3
B
(60)
CIS-DIAMMINEDICHLOROPLATINUM II
Pancreatic Ductal Adenocarcinoma
Jonsson Comprehensive Cancer Center
P2/3
B
(60)
Carboplatin
Pancreatic Ductal Adenocarcinoma
Akeso
P2
B
(59)
Nivolumab
Pancreatic Ductal Adenocarcinoma
Georgetown University
P2
B
(59)
Cetuximab
Pancreatic Ductal Adenocarcinoma
Verastem, Inc.
P2
B
(57)
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Pancreatic Ductal Adenocarcinoma
Brian Anderson, MD
P4
B
(56)
Epirubicin
Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb
P2
B
(56)
Levoleucovorin
Pancreatic Ductal Adenocarcinoma
Shenzhen Xinhe Biomedical
P2
B
(56)
Pembrolizumab
Pancreatic Ductal Adenocarcinoma
GV20 Therapeutics
P2
B
(56)
Floxuridine
Pancreatic Ductal Adenocarcinoma
Duke University
P4
CCC
(55)
Inno-206
Pancreatic Ductal Adenocarcinoma
ImmunityBio, Inc.
P2
CCC
(55)
Olaparib
Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
P2
CCC
(55)
Immuncell-Lc
Pancreatic Ductal Adenocarcinoma
GC Cell Corporation
P3
CCC
(52)
N-BUTYL CYANOACRYLATE
Pancreatic Ductal Adenocarcinoma
Minia University
P3
CCC
(52)
FILGRASTIM
Pancreatic Ductal Adenocarcinoma
Georgetown University
P2
CCC
(52)
Gdc-0449
Pancreatic Ductal Adenocarcinoma
Mayo Clinic
P2
CCC
(52)
Sacituzumab Tirumotecan
Pancreatic Ductal Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P2
CCC
(52)
vs-7375
Pancreatic Ductal Adenocarcinoma
Verastem, Inc.
P2
CCC
(52)
Showing 1 to 25 of 149 assets
Previous
Page 1 of 6
Next
